Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 36

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 36
---
) 4,570,629 shares of our Common Stock and (ii) 4,750,916 shares of our Common Stock issuable upon the exercise of warrants. The shares of Common Stock have been issued or are issuable in connection (i) the Securities Purchase Agreement dated as of June 2, 2025 (the “Securities Purchase Agreement”), (ii) a selling stockholder’s exercise of warrants to purchase 45,765 shares of Common Stock, and (iii) placement agent warrants issued in connection with the Private Placement (see definition below). We are registering the shares of Common Stock in order to permit the selling stockholders to offer the shares for resale from time to time in accordance with the terms of the Securities Purchase Agreement. On June 2, 2025, we and the selling stockholders (the “Purchasers”) entered into the Securities Purchase Agreement pursuant to which we agreed to issue to the Purchasers, in a private placement (the “Private Placement”), an aggregate of 4,759,309 shares of Common Stock together with warrants to purchase an equal number of shares of Common Stock at an exercise price of $3.3125 (the “Private Placement Warrants”), for an aggregate offering amount of approximately $12.6 million. The combined effective offering price for each share and accompanying Private Placement Warrant in the Private Placement was $2.65. Pursuant to the Securities Purchase Agreement, each Purchaser was obligated to purchase such Purchaser’s respective investment in the Private Placement in four equal tranches, as follows:

| • |     | $2.23 million was purchased on June 2, 2025 (the “Initial Closing”); |

| • |     | $2.23 million was purchased on June 9, 2025, following our notification to the Purchasers that the Food                                                                                                                                          
 and Drug Administration (FDA) has notified us that we are no longer subject to the partial clinical hold set forth in the FDA’s Partial Clinical Hold letter to us dated January 24, 2024, with respect to our planned Phase 3 trial of IFx-2.0; |

| • |     | $2.23 million was purchased on June 24, 2025, following our notification to the Purchasers that the 
 Phase 3 trial for IFx-Hu2.0 (the “Phase 3 Trial”) had been initiated; and                           |

| • |     | $2.23 million was purchased on June 30,